SCHEMBL4044491

SCHEMBL4044491

O=C(NC1CCCCC1)C(c1cc(F)ccc1F)C1(c2ccc(Cl)cc2)Nc2ccccc2N1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
POLB P06746 2/20 0.40
CNR1 P21554 6/20 0.39
CNR2 P34972 3/20 0.39
CYP3A4 P08684 2/20 0.38
KCNH2 Q12809 2/20 0.38
NR1H4 Q96RI1 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2D6 P10635 1/20 0.38
EPHX2 P34913 2/20 0.36
EPHX1 P07099 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4036130 0.88 NR1H4 (0.42) KMT2AMEN1NPC1RAB9ACNR1
SCHEMBL4038946 0.87 OPRL1 (0.41) KMT2AMEN1NPC1RAB9ACNR1
SCHEMBL4044209 0.84 HRH3 (0.43) NPC1RAB9APOLBCNR1NR1H4
SCHEMBL4042732 0.82 NR1H4 (0.44) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL4039101 0.82 NR1H4 (0.44) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL4036796 0.81 NPC1 (0.41) NPC1RAB9APOLBCNR1CNR2
SCHEMBL4036972 0.81 NPC1 (0.41) NPC1RAB9APOLBCNR1CNR2
SCHEMBL4040060 0.81 LMNA (0.48) NPC1RAB9ACNR1CNR2ALDH1A1
SCHEMBL4038094 0.80 TSHR (0.45) KMT2AMEN1CNR1CNR2CYP2C9
SCHEMBL4040480 0.80 NR1H4 (0.44) NPC1RAB9APOLBCYP3A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed